Jyong Biotech Ltd. (MENS)
NASDAQ: MENSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
MENS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $159.66M
- EPS (TTM)
- -$0.06
- Dividend yield
- None
- 52-week range
- 1.43 – 63.00
- Day range
- 2.00 – 2.12
- Volume / Avg
- 39.25K / 45.62K
- Beta
- —
- Shares outstanding
- 74.23M
- Next earnings
- Nov 12, 2026
52-week range
MENS stock today
Shares of Jyong Biotech (MENS) finished higher on Oct 8 at $2.10, a gain of 2.44% or $0.05 per share, versus the S&P 500's 0.47% decline. Shares are 96.7% below their 52-week high of $63.00, set on Oct 23, 2025 and 46.9% above the 52-week low of $1.43, near the bottom of the past year's range. MENS is down 47.8% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 96.3%.
Jyong Biotech has posted a net loss over the last twelve months (EPS of -$0.06), so its P/E ratio is not meaningful. Jyong Biotech's next earnings report is expected on Nov 12, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Jyong Biotech
Company profileJyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Fu-Feng Kuo
- Headquarters
- New Taipei City
- Employees
- 27
- IPO year
- 2025
- Website
- jyongbio.com
Earnings
Earnings history- Next report
- Nov 12, 2026
Jyong Biotech peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KRROKorro Bio Inc. | 10.58 | +0.86% | $155.80M | vs MENS |
| NBPNovaBridge Biosciences ADR | 1.37 | 0.00% | $158.92M | vs MENS |
| NKTXNkarta Inc. | 2.22 | -2.20% | $159.01M | vs MENS |
| VRXAVeraxa Biotech AG | 1.09 | -9.17% | $154.13M | vs MENS |
| NERVMinerva Neurosciences Inc | 3.22 | -1.53% | $153.75M | vs MENS |
| EMISEmmis Acquisition Corp. Class A | 10.27 | 0.00% | $162.02M | vs MENS |
| CUECue Biopharma Inc. | 22.33 | -0.80% | $162.21M | vs MENS |
| ALXOALX Oncology Holdings Inc. | 1.18 | +4.42% | $163.17M | vs MENS |
Indexes, lists and sector
Jyong Biotech stock FAQ
What is Jyong Biotech's stock price today?
MENS last traded at $2.10 as of Oct 8, 4:00 PM EDT, up 2.44% on the day. Prices are delayed at least 15 minutes.
When is Jyong Biotech's next earnings date?
Jyong Biotech is expected to report earnings on Thursday, November 12, 2026.
Who is Jyong Biotech's CEO?
Ms. Fu-Feng Kuo is the chief executive officer of Jyong Biotech Ltd., which has about 27 employees.
What is the MENS 52-week high?
The 52-week high for MENS is $63.00 and the 52-week low is $1.43. The stock is currently 96.7% below its high.